Skip to main content

Abcellera Biologics Inc(ABCL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low7.48
Day High7.65
Open:7.62
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDFRefinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDFStockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Premium PDFValueEngine

Press & news

Latest News

More Stories
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
Business Wire - Wed Mar 22, 8:00AM CDT
Business Wire
Wed Mar 22, 8:00AM CDT
AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and...
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
Business Wire - Tue Mar 14, 3:30PM CDT
Business Wire
Tue Mar 14, 3:30PM CDT
AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando,...
Tuesday’s analyst upgrades and downgrades
The Globe and Mail - Tue Feb 28, 6:00AM CST
The Globe and Mail
Tue Feb 28, 6:00AM CST
Inside the Market’s roundup of some of today’s key analyst actions

Latest Articles

Tuesday’s analyst upgrades and downgrades
Friday’s analyst upgrades and downgrades
Market movers: Stocks that saw action on Thursday - and why
Setback for B.C.’s AbCellera as FDA pulls U.S. authorization for its COVID-19 antibody
Market movers: Stocks that saw action on Wednesday - and why
AbCellera posts another strong quarter of COVID-19 antibody sales – but new variants could affect 2023 revenue
AbCellera is not a COVID-19 company, CEO insists, even as Canadian developer reaps windfall from pandemic treatments
Xenon Pharmaceuticals shares soar on strong results for epilepsy drug
AbCellera posts second-quarter loss as revenue tumbles
Vancouver’s AbCellera reaps windfall from COVID-19 antibody royalties, sees demand ‘for years to come’
Vancouver biotech firm AbCellera made nearly $200-million in royalties in 2020 from its COVID-19 treatment
RBC taps into biotech surge, investing in new Lumira venture fund

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.